首页> 外文期刊>Japanese Journal of Ophthalmology >Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma.
【24h】

Additive effect of bunazosin on intraocular pressure when topically added to treatment with latanoprost in patients with glaucoma.

机译:青光眼患者局部加用拉坦前列素治疗时布尼唑嗪对眼压的累加作用。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To investigate whether an alpha-1 blocker, bunazosin, has an additive effect on lowering intraocular pressure (IOP) when topically added to latanoprost treatment in patients with glaucoma. METHODS: Bunazosin twice a day was added topically to the treatment for 12 patients with glaucoma who had been instilling latanoprost once a day for more than 1 month. IOP was measured and adverse events were checked 2, 4 and 8 weeks after the addition of bunazosin to their treatment. RESULTS: One of the 12 patients dropped out in the course of the study. Therefore, 11 patients were included for the analysis of IOP, and 12 for the analysis of adverse events. IOPs were decreased significantly (P=.008, Wilcoxon signed rank test) from 18.2+/-3.4 mm Hg to 16.6+/-3.5 mm Hg 8 weeks after the addition of bunazosin. Adverse events were seen in 5 of the 12 patients. CONCLUSION: Bunazosin has an additive effect on lowering IOP when topically added to latanoprost treatment in glaucoma patients.
机译:目的:研究青光眼患者局部使用拉坦前列素治疗时,α-1阻滞剂布那唑嗪是否对降低眼内压(IOP)有加成作用。方法:每天两次向治疗青光眼的患者中每日两次加用布那唑嗪,这些患者每天一次输注拉坦前列素超过1个月。在将布氮唑嗪加入治疗后的2、4和8周,测量眼压并检查不良事件。结果:12名患者中的1名在研究过程中辍学。因此,包括11位患者用于IOP分析,12位患者用于不良事件分析。加入布氮唑嗪后8周,眼压显着降低(P = .008,Wilcoxon符号秩检验),从18.2 +/- 3.4 mm Hg降至16.6 +/- 3.5 mm Hg。 12名患者中有5名出现了不良事件。结论:在青光眼患者中局部应用拉坦前列素治疗时,布那唑嗪具有降低眼压的累加作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号